Method to Amplify Tumor-Associated Antigens Developed

Tumor immunotherapies that rely on T cells to identify and eliminate cancer cells have achieved important advances but continue to face significant challenges. Many tumor-associated antigens are present at very low levels on cancer cell surfaces, which prevents strong T-cell activation. Complicating matters further, these antigens can also appear in healthy tissues, reducing treatment specificity and creating the risk of off-target toxicity.

A recent Nature study led by researchers from the Chinese Academy of Sciences introduced a novel cell-surface protein engineering strategy called Proximity Amplification and Tagging of Cytotoxic Haptens (PATCH) to overcome these limitations. The team repurposed proximity labeling—traditionally a chemical biology method for mapping protein interactions—as a way to modify tumor cells so that they can be more easily recognized by the immune system.

The PATCH approach begins with an engineered nanozyme (PCN) directed to the surface of tumor cells. This nanozyme can be precisely activated by external red light or ultrasound. Once activated, it catalyzes the covalent bonding of probe molecules containing an artificial antigen, fluorescein isothiocyanate (FITC), to proteins within just a few nanometers of the tumor membrane. This process effectively “plants” a dense cluster of artificial antigens on the cancer cell surface.

These antigen clusters act as a concentrated signal for T cells. When paired with a bispecific T-cell engager (BiTE) that links FITC to the CD3 molecule found on T cells, the clusters attract and aggregate T-cell receptors. This strong recruitment substantially boosts T-cell activation and enables them to efficiently kill tumor cells.

Experiments in solid-tumor animal models and patient-derived tumor samples showed that the PATCH strategy successfully eradicated tumors at the treated site. Beyond local effects, it also triggered systemic immune responses. Destroyed tumor cells released additional antigens into circulation, prompting the immune system to attack distant, untreated tumors in an “abscopal effect.” The immune memory generated by this process then offered durable protection against recurrence.

By adapting proximity labeling into a functional immune modulation tool, this strategy addresses the barrier of insufficient antigen density on tumors while maintaining high treatment specificity. The results expand the range of potential immunotherapy targets and suggest a precise and efficient path forward for next-generation cancer treatments.